Implementing total-dose ferumoxytol in lieu of split-dose ferumoxytol

Hsin, Jerline; Au, Lara; Lustik, Michael B.; Miles, Daniel; Kim, Myung-Jin; Miloni, Cathy; Layman, Clifton

doi:10.1016/j.japh.2021.07.008

Cited by 1 publication

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies also report the use of a single 1020 mg dose. [92][93][94][95] One study recently reported the outcomes of 131 iron-deficient secondand third-trimester pregnant individuals who received either 510 mg of IV ferumoxytol twice or 1020 mg once. 96 Among all infusions of 1020 or 510 mg, minor infusion reactions were observed in 19 (14%), of which 11 occurred with the 510 mg infusion, and 8 with the 1020 mg infusion.…”

Section: Ferumoxytolmentioning

confidence: 99%

See 1 more Smart Citation

The incidence, complications, and treatment of iron deficiency in pregnancy

Benson

Shatzel

Ryan

et al. 2022

European J of Haematology

View full text Add to dashboard Cite

Iron deficiency and/or iron deficiency anemia (IDA) complicate nearly 50% of pregnancies globally, negatively impacting both maternal and fetal outcomes. Iron deficiency can cause a range of symptoms that range from aggravating to debilitating including fatigue, poor quality of life, pagophagia, and restless leg syndrome. Iron deficiency and IDA are also associated with maternal complications including preterm labor, increased rates of cesarean delivery, postpartum hemorrhage, and maternal death. Fetal complications include increased rates of low birth weight and small for gestational age newborns. Prenatal maternal anemia has also been associated with autism spectrum disorders in the neonate, although causation is not established. Deficiency in the newborn is associated with compromised memory, processing, and bonding, with some of these deficits persisting into adulthood. Despite the prevalence and consequences associated with iron deficiency in pregnancy, data show that it is routinely undertreated. Due to the physiologic changes of pregnancy, all pregnant individuals should receive oral iron supplementation. However, the bioavailability of oral iron is poor and it is often ineffective at preventing and treating iron deficiency. Likewise, it frequently causes gastrointestinal symptoms that can worsen the quality of life in pregnancy. Intravenous iron formulations administered in a single or multiple dose series are now available. There is increasing data suggesting that newer intravenous formulations are safe and effective in the second and third trimesters and should be strongly considered in pregnant individuals without optimal response to oral iron repletion.

show abstract

Section: Ferumoxytolmentioning

confidence: 99%

“…Ferumoxytol can be given as two 510 mg doses approximately a week apart. Several studies also report the use of a single 1020 mg dose 92–95 . One study recently reported the outcomes of 131 iron‐deficient second‐ and third‐trimester pregnant individuals who received either 510 mg of IV ferumoxytol twice or 1020 mg once 96 .…”

Section: Introductionmentioning

confidence: 99%